Comparative activity of pradofloxacin and marbofloxacin against coagulase-positive staphylococci in a pharmacokinetic-pharmacodynamic model based on canine pharmacokinetics

Journal of Veterinary Pharmacology and Therapeutics

Volumn 35, Issue 6, 2012, Pages 571-579

  Korber Irrgang B ^a   Wetzstein, H G ^b   Bagel Trah, S ^a   Hafner, D ^c   Kresken, M ^a  

^a Antiinfectives Intelligence GmbH   (Germany)

^b BAYER AG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MARBOFLOXACIN; PRADOFLOXACIN;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; COAGULASE POSITIVE STAPHYLOCOCCUS; COAGULASE POSITIVE STAPHYLOCOCCUS INFECTION; COLONY FORMING UNIT; DOG; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SERUM; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS INTERMEDIUS;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOGS; FLUOROQUINOLONES; HALF-LIFE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCUS;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PSEUDINTERMEDIUS;

EID: 84868682790     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2011.01361.x     Document Type: Article

References (41)

1. Abraham, J., Ewert, K. & de Jong, A. (2002) Pradofloxacin: comparative in vitro activity against selected pathogens from the US. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. p. 189, poster F-568. American Society for Microbiology, Washington, DC.
2. Bannoehr, J., Franco, A., Iurescia, M., Battisti, A. & Fitzgerald, J.R. (2009) Molecular diagnostic identification of Staphylococcus pseudintermedius. Journal of Clinical Microbiology, 47, 469-471.
3. Bidgood, T.L. & Papich, M.G. (2005) Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs. Journal of Veterinary Pharmacology and Therapeutics, 28, 329-341.
4. Blondeau, J.M. (1999) A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. Journal of Antimicrobial Chemotherapy, 43 (Suppl B), 1-11.
5. Bregante, M.A., de Jong, A., Aramayona, J.J., Garcia, M.A., Solans, C. & Rueda, S. (2000) Protein binding of fluoroquinolones applied to livestock and companion animals. In Proceedings of the 8th International Congress European Asssociation for Veterinary Pharmacology and Toxicology (EAVPT), Jerusalem, Israel. p. 88.
6. Bregante, M.A., de Jong, A., Calvo, A., Hernandez, E., Rey, R. & Garcia, M.A. (2003) Protein binding of pradofloxacin, a novel 8-cyanofluoroquinolone, in dog and cat plasma. Journal of Veterinary Pharmacology and Therapeutics, 26 (Suppl 1), 87-88.
7. Cester, C.C., Schneider, M. & Toutain, P.L. (1996) Comparative kinetics of two orally administered fluoroquinolones in dog: enrofloxacin versus marbofloxacin. Revue de Medecine Veterinaire, 147, 703-716.
8. Clinical and Laboratory Standards Institute. (2006) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A5. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Craig, W.A. (2001) Does the dose matter? Clinical Infectious Diseases, 33 (Suppl. 3), 233-237.
10. DeBoer, D.J. (1990) Strategies for management of recurrent pyoderma in dogs. The Veterinary Clinics of North America. Small Animal Practice, 20, 1509-1524.
11. Descloux, S., Rossano, A. & Perreten, V. (2008) Characterization of new staphylococcal cassette chromosome mec (SCCmec) and topoisomerase genes in fluoroquinolone- and methicillin-resistant Staphylococcus pseudintermedius. Journal of Clinical Microbiology, 46, 1818-1823.
12. Drlica, K. & Malik, M. (2003) Fluoroquinolones: action and resistance. Current Topics in Medicinal Chemistry, 3, 249-282.
13. Fitzgerald, J.R. (2009) The Staphylococcus intermedius group of bacterial pathogens: species re-classification, pathogenesis and the emergence of methicillin resistance. Veterinary Dermatology, 20, 490-495.
14. Fraatz, K., Heinen, K., Krebber, R., Edingloh, M. & Heinen, E. (2002). Serum pharmacokinetics of pradofloxacin in dogs after multiple oral administrations at various dosages. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. p. 189. American Society for Microbiology, San Diego, CA.
15. Grasso, S., Meinardi, G., de Carneri, I. & Tamassia, V. (1978) New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrobial Agents and Chemotherapy, 13, 570-576.
16. Homma, T., Hori, T., Sugimori, G. & Yamano, Y. (2007) Pharmycodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 51, 3810-3815.
17. Horspool, L.J.I., van Laar, P., van den Bos, R. & Mawhinney, I. (2004) Treatment of canine pyoderma with ibafloxacin and marbofloxacin - fluoroquinolones with different pharmacokinetic profiles. Journal of Veterinary Pharmacology and Therapeutics, 27, 147-153.
18. Keil, S. & Wiedemann, B. (1995) Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models. Antimicrobial Agents and Chemotherapy, 39, 1054-1058.
19. Koerber, B., Luhmer, E., Wetzstein, H.G. & Heisig, P. (2002). Bactericidal mechanisms of pradofloxacin, a novel 8-cyanofluoroquinolone. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. p. 188, poster F-567. American Society for Microbiology, Washington, DC.
20. Liang, B., Bai, N., Cai, Y., Wang, R., Drlica, K. & Zhao, X. (2011) Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 55, 2409-2412.
21. Lu, T., Zhao, X. & Drlica, K. (1999) Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrobial Agents and Chemotherapy, 43, 2969-2974.
22. Lu, T., Zhao, X., Li, X., Drlica-Wagner, A., Wang, J.Y., Domagala, J. & Drlica, K. (2001) Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 45, 2703-2709.
23. Lund, E.M., Armstrong, P.J., Kirk, C.A., Kolar, L.M. & Klausner, J.S. (1999) Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. Journal of the American Animal Hospital Association, 214, 1336-1341.
24. McKellar, Q.A., Sanchez Bruni, S.F. & Jones, D.G. (2004) Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics, 27, 503-514.
25. Morris, D.O., Rook, K.A., Shofer, F.S. & Rankin, S.C. (2006) Screening of Staphylococcus aureus, Staphylococcus intermedius, and Staphylococcus schleiferi isolates obtained from small companion animals for antimicrobial resistance: retrospective review of 749 isolates (2003-04). Veterinary Dermatology, 17, 332-337.
26. Mueller, R.S. & Stephan, B. (2007) Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial. Veterinary Dermatology, 18, 144-151.
27. NN (2003) USP Veterinary Pharmaceutical Information Monographs - Antibiotics. Journal of Veterinary Pharmacology and Therapeutics, 26 (Suppl 2), 1-271.
28. Restrepo, C., Ihrke, P.J., White, S.D., Spiegel, I.B. & Affolter, V.K. (2010) Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma. Journal of the American Animal Hospital Association, 46, 301-311.
29. Schwarz, S., Alesik, E., Werckenthin, C., Grobbel, M., Lübke-Becker, A., Wieler, L.H. & Wallmann, J. (2007) Antimicrobial susceptibility of coagulase-positive and coagulase-variable staphylococci from various indications of swine, dogs and cats as determined in the BfT-GermVet monitoring program 2004-2006. Berliner und Münchner tierärztliche Wochenschrift, 120, 372-379.
30. Scott, D.W. & Paradis, M. (1990) A survey of canine and feline skin disorders seen in a university practice: small animal clinic, University of Montreal, St Hyacinthe, Quebec (1987-88). Canadian Veterinary Journal, 31, 830-835.
31. Scott, D.W., Miller, W.H. Jr & Griffin, C.E. (2001) In Muller and Kir's Small Animal Dermatology, 6th edn. pp. 453-457. Saunders Elsevier, Philadelphia.
32. Silley, P., Stephan, B., Greife, H.A. & Pridmore, A. (2007) Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. Journal of Antimicrobial Chemotherapy, 60, 999-1003.
33. Spindel, M.E., Veir, J.K., Radecki, S.V. & Lappin, M.R. (2008) Evaluation of pradofloxacin for the treatment of feline rhinitis. Journal of Feline Medicine and Surgery, 10, 472-479.
34. Stephan, B., Hellmann, K., Liège, P., Granier, S., Knoppe, T.N., Heinen, E. & Greife, H.A. (2003) Clinical efficacy and safety of pradofloxacin in the treatment of canine pyoderma and wound infections under field conditions. Journal of Veterinary Pharmacology and Therapeutics, 26 (Suppl. 1), 217-218.
35. Stephan, B., Friederichs, S., Pridmore, A., Roy, O., Edingloh, M. & Greife, H.A. (2006a) Treatment of canine cystitis and prostatitis with pradofloxacin: clinical and microbiological results. Journal of Veterinary Pharmacology and Therapeutics, 29 (Suppl. 1), 75-76.
36. Stephan, B., Friederichs, S., Pridmore, A., Hellmann, K., Adler, K., Edingloh, M. & Greife, H.A. (2006b) Novel fluoroquinolone pradofloxacin: clinical efficacy and safety in the treatment of feline wound infections and abscesses. Journal of Veterinary Pharmacology and Therapeutics, 29 (Suppl. 1), 77-78.
37. Wetzstein, H.G. (2005) Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicating differing potentials in preventing selection of resistance. Antimicrobial Agents and Chemotherapy, 49, 4166-4173.
38. Wetzstein, H.-G. (2008) Pradofloxacin causes a pronounced postantibiotic sub-MIC effect in high-density bacterial populations. In Abstracts 108th General Meeting, p. 723, poster Z-033. American Society for Microbiology, Washington, DC.
39. Wright, D.H., Brown, G.H., Peterson, M.L. & Rotschafter, J.C. (2000) Application of fluoroquinolone pharmacodynamics. Journal of Antimicrobial Chemotherapy, 46, 669-683.
40. 0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. Journal of Antimicrobial Chemotherapy, 51, 905-911.
41. Zinner, S.H. & Firsov, A.A. (1999) In vitro dynamic model for determining the comparative pharmacology of flouroquinolones. American Journal of Health-System Pharmacy, 56, 12-15.